Market Cap : 35.71 B | Enterprise Value : 34.94 B | PE Ratio : 49.40 | PB Ratio : 3.29 |
---|
NAS:ILMN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ILMN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2022-08-10), Illumina's share price is $227.30. Illumina's Tangible Book per Share of Mar. 2022 for the quarter that ended in Mar. 2022 was $3.65. Hence, Illumina's Price to Tangible Book Ratio of today is 62.31.
The historical rank and industry rank for Illumina's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Illumina's highest Price to Tangible Book Ratio was 461.34. The lowest was 1.17. And the median was 12.83.
A closely related ratio is called PB Ratio. As of today, Illumina's share price is $227.30. Illumina's Book Value per Sharefor the quarter that ended in Mar. 2022 was $69.36. Hence, Illumina's P/B Ratio of today is 3.28.
The historical data trend for Illumina's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Illumina's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Illumina's Price-to-Tangible-Book falls into.
Illumina's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Mar. 2022 ) |
= | 227.30 | / | 3.648 | |
= | 62.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Illumina's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Frank John Edward | officer: Chief Public Affairs Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Rollins Carissa | officer: SVP, Chief Information Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Pegels Kevin Carl | officer: Chief of Global Operations | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Torres Jose | officer: VP, Chief Accounting Officer | 1300 W. 120TH AVENUE WESTMINSTER CO 80234 |
Reeves Kathryne Gambrell | officer: SVP, Chief Marketing Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Aravanis Alexander | officer: SVP, Chief Technology Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Gottlieb Scott | director | MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142 |
Febbo Phillip G. | officer: SVP Chief Medical Officer | C/O GENOMIC HEALTH, INC. 301 PENOBSCOT DRIVE REDWOOD CITY CA 94063 |
Tousi Susan H | officer: SVP Product Development | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Goswami Joydeep | officer: SVP Corp Business Development | SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023 |
Siegel Susan E | director | 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025 |
Ragusa Robert P | officer: SVP, Global Quality & Ops | |
Hoyt Aimee L | officer: SVP, Chief People Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Guthart Gary S | director | C/O INTUITIVE SURGICAL INC 1266 KIFER RD SUNNYVALE CA 94086 |
Mcginnis Karen K | officer: VP, Chief Accounting Officer | INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284 |
From GuruFocus
By PRNewswire 02-21-2022
By PRNewswire 02-03-2022
Other Sources
By Zacks 2022-03-18
By Zacks 2022-02-10
By Zacks 2022-01-05
By Zacks 2022-01-07
By Fool 2022-01-22
By Zacks 2022-02-11
By Zacks 2022-02-07
By Zacks 2022-02-18
By Zacks 2022-02-03
By Zacks 2021-12-15
By Zacks 2022-01-13
By Seekingalpha 2022-02-10
By Zacks 2022-01-11
By Zacks 2021-12-27